SCOTT M ROCKLAGE
CIK 1219014 · last filed 2024-03-15
SCOTT M ROCKLAGE is a corporate insider who has filed 29 SEC Form 4 insider transactions across 14 companies since 2013. Across all open-market trades the lifetime net is +$11.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $52.7M across reported positions. 71 SEC filings were submitted jointly with Andrew J. Schwab.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$52.72M
14
29
$11.89M
Filer Profile
4 EMBARCADERO CENTER, SUITE 3110
SAN FRANCISCO, CA 94111
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RLYB | 10%+ Owner | 156,469 | $16.88 | $2.64M | -$19.72M | 2 | 2023-03-09 |
| Pear Therapeutics, Inc. (PEARW) Delisted | 10%+ Owner | 537,406 | $0.01 | $3.2K | -$2.31M | 1 | 2022-11-15 |
| Akouos, Inc. (AKUS) Delisted | 10%+ Owner | 3,153,331 | $13.29 | $41.91M | -$50.76M | 1 | 2020-12-31 |
| APRE | Director | 3,798 | $0.77 | $2.9K | -$20.01M | 5 | 2020-07-01 |
| CABA | 10%+ Owner | 3,214,721 | $2.73 | $8.78M | $35.00M | 1 | 2019-10-31 |
| IDYA | 10%+ Owner | 84,420 | $37.59 | $3.17M | $37.50M | 1 | 2019-05-28 |
| ARVN | 10%+ Owner | 4,512,136 | $8.45 | $38.13M | -$30.68M | 1 | 2019-04-01 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | — | $221.38 | — | $0 | 4 | 2018-06-15 |
| scPharmaceuticals Inc. (SCPH) Delisted | 10%+ Owner | 103,945 | $5.67 | $589.4K | $55.00M | 1 | 2017-11-21 |
| PULM | Director | 844 | $1.41 | $1.2K | $266.8K | 4 | 2016-02-25 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Director | 2,549,211 | — | — | $2.00M | 2 | 2015-06-08 |
| VIVEVE MEDICAL, INC. (TCON) Delisted | 10%+ Owner | 36,551 | $0.03 | $1.2K | $1.50M | 1 | 2015-05-29 |
| Achaogen, Inc. (AKAO) Delisted | Director | — | — | — | $0 | 1 | 2014-03-13 |
| Relypsa Inc (RLYP) Delisted | Director | 2,258,376 | — | — | $4.10M | 2 | 2013-11-20 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-15 | — | Buy (P) | +3,600,000 | $36.00M | |
| 2024-02-02 | — | Buy (P) | +41,648,592 | $96.21M | |
| 2023-03-09 | RLYB | Sell (S) | −400,000 | -$3.28M | EDGAR |
| 2022-11-15 | Pear Therapeutics, Inc. (PEARW) Delisted | Sell (S) | −842,248 | -$2.31M | EDGAR |
| 2022-02-10 | RLYB | Sell (S) | −1,260,000 | -$16.44M | EDGAR |
| 2020-12-31 | Akouos, Inc. (AKUS) Delisted | Sell (S) | −2,820,000 | -$50.76M | EDGAR |
| 2020-07-01 | APRE | Grant (A) | — | $0 | EDGAR |
| 2020-06-18 | APRE | Sell (S) | −120,164 | -$4.00M | EDGAR |
| 2020-06-15 | APRE | Sell (S) | −245,000 | -$7.04M | EDGAR |
| 2020-05-21 | APRE | Sell (S) | −255,000 | -$8.96M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.